Introduction Levofloxacin in the Medical Management of Community-acquired Pneumonia

20 June, 2018

The medical management of community-acquired pneumonia (or CAP) is presently undergoing a general review, driven primarily by the increasing incidence of resistant pathogens, along with the realization that atypical bacteria may have a greater role to play in the etiology of CAP. This has led to the need for agents, such as the newer fluoroquinolones, which have sustained activity against these pathogens. To discuss the medical management of CAP in adults, Professor Andy Hoepelman, Department of Acute Medicine and Infectious Diseases, University Medical Center, Utrecht, the Netherlands, was interviewed. Professor Hoepelman summarized the current situation in regard to CAP, outlining the etiological trends, diagnostic features and optimal treatment strategies for managing this important disease.